Login / Signup

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.

Slavomir KrajnakThomas DeckerLukas SchollenbergerChristian RoséChristian RuckesTanja FehmChristoph ThomssenNadia HarbeckMarcus Schmidt
Published in: Journal of cancer research and clinical oncology (2021)
ClinicalTrials.gov Identifier: NCT03007992; December 15, 2016.
Keyphrases
  • phase ii study
  • locally advanced
  • open label
  • squamous cell carcinoma
  • rectal cancer
  • small cell lung cancer
  • radiation therapy
  • physical activity
  • placebo controlled
  • stem cells
  • combination therapy
  • study protocol